Cargando…

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension

In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin re...

Descripción completa

Detalles Bibliográficos
Autor principal: Greathouse, Mark
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994014/
https://www.ncbi.nlm.nih.gov/pubmed/17323594
_version_ 1782135468694962176
author Greathouse, Mark
author_facet Greathouse, Mark
author_sort Greathouse, Mark
collection PubMed
description In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a β-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor. One such combination is olmesartan medoxomil + HCTZ, which is available as fixed-dose, single-tablet combinations for once-daily administration. In clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP) to a greater extent than either component as monotherapy. A clinical study in patients with Stage 1 or 2 hypertension showed that olmesartan medoxomil/HCTZ achieved a similar mean reduction in DBP, but a significantly greater mean reduction in SBP and higher rate of BP control (<140/90 mmHg) than observed with losartan/HCTZ, at US/European-approved starting doses. In a non-inferiority trial, the antihypertensive efficacy of olmesartan medoxomil/HCTZ was comparable to that of atenolol/HCTZ. Furthermore, indirect comparisons have shown that olmesartan medoxomil/HCTZ compares favorably with other antihypertensive combination therapies, including other ARB/HCTZ combinations and amlodipine besylate/benazepril. Olmesartan medoxomil/HCTZ is generally well tolerated. In conclusion, olmesartan medoxomil/HCTZ is an effective and well-tolerated combination antihypertensive therapy that results in significant BP reductions and BP control in many patients.
format Text
id pubmed-1994014
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-19940142008-03-06 Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension Greathouse, Mark Vasc Health Risk Manag Review In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a β-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor. One such combination is olmesartan medoxomil + HCTZ, which is available as fixed-dose, single-tablet combinations for once-daily administration. In clinical trials, olmesartan medoxomil/HCTZ reduced systolic BP (SBP) and diastolic BP (DBP) to a greater extent than either component as monotherapy. A clinical study in patients with Stage 1 or 2 hypertension showed that olmesartan medoxomil/HCTZ achieved a similar mean reduction in DBP, but a significantly greater mean reduction in SBP and higher rate of BP control (<140/90 mmHg) than observed with losartan/HCTZ, at US/European-approved starting doses. In a non-inferiority trial, the antihypertensive efficacy of olmesartan medoxomil/HCTZ was comparable to that of atenolol/HCTZ. Furthermore, indirect comparisons have shown that olmesartan medoxomil/HCTZ compares favorably with other antihypertensive combination therapies, including other ARB/HCTZ combinations and amlodipine besylate/benazepril. Olmesartan medoxomil/HCTZ is generally well tolerated. In conclusion, olmesartan medoxomil/HCTZ is an effective and well-tolerated combination antihypertensive therapy that results in significant BP reductions and BP control in many patients. Dove Medical Press 2006-12 2006-12 /pmc/articles/PMC1994014/ /pubmed/17323594 Text en © 2006 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Greathouse, Mark
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title_full Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title_fullStr Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title_full_unstemmed Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title_short Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
title_sort olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994014/
https://www.ncbi.nlm.nih.gov/pubmed/17323594
work_keys_str_mv AT greathousemark olmesartanmedoxomilcombinedwithhydrochlorothiazideforthetreatmentofhypertension